Data from SCOPE, examining Scancell’s highly promising ImmunoBody “off-the-shelf” DNA cancer vaccine, appear to show that a meaningful, additional benefit can be achieved when added to standard-of-care (SoC) CPIs as a first-line treatment in advanced melanoma. iSCIB1+ has been selected as the candidate for further development; it works in a larger, and easily identifiable, patient group that represents 80% of all advanced melanomas, double that of SCIB1. The benefits of iSCIB1+ will need to be demonstrated in a controlled trial (SCOPE was an open-label, exploratory trial), and development plans for a Phase IIb/III registrational study are being accelerated. Our valuation is increased >10% to £373m, or 36p/share following the latest SCOPE data. Further SCOPE data are expected later this year, as well as early data from the renal cell carcinoma (RCC) cohort of the ModiFY study, with upside potential from both.
